NDC 68084-752

Clopidogrel

Clopidogrel Bisulfate

Clopidogrel is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by American Health Packaging. The primary component is Clopidogrel Bisulfate.

Product ID68084-752_84eb7545-2166-0960-e053-2991aa0a902a
NDC68084-752
Product TypeHuman Prescription Drug
Proprietary NameClopidogrel
Generic NameClopidogrel Bisulfate
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2014-03-28
Marketing CategoryANDA / ANDA
Application NumberANDA076274
Labeler NameAmerican Health Packaging
Substance NameCLOPIDOGREL BISULFATE
Active Ingredient Strength300 mg/1
Pharm ClassesDecreased Platelet Aggregation [PE],P2Y12 Platelet Inhibitor [EPC],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 2C8 Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 68084-752-25

30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-752-25) > 1 TABLET, FILM COATED in 1 BLISTER PACK (68084-752-95)
Marketing Start Date2014-03-28
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 68084-752-25 [68084075225]

Clopidogrel TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA076274
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2014-03-28

NDC 68084-752-95 [68084075295]

Clopidogrel TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA076274
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2014-03-28

Drug Details

Active Ingredients

IngredientStrength
CLOPIDOGREL BISULFATE300 mg/1

OpenFDA Data

SPL SET ID:65ea4dc6-acb2-4609-9a4c-4866ef0ccb11
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 749196
  • 309362
  • Pharmacological Class

    • Decreased Platelet Aggregation [PE]
    • P2Y12 Platelet Inhibitor [EPC]
    • P2Y12 Receptor Antagonists [MoA]
    • Cytochrome P450 2C8 Inhibitors [MoA]
    • Decreased Platelet Aggregation [PE]
    • P2Y12 Platelet Inhibitor [EPC]
    • P2Y12 Receptor Antagonists [MoA]
    • Cytochrome P450 2C8 Inhibitors [MoA]